Close Menu

NEW YORK (GenomeWeb) – Invitae reported after the close of the market Tuesday a nearly 14 percent decline in second quarter revenues from the prior year, which was still better than the consensus Wall Street estimate.

For the three months ended June 30, the firm generated $46.2 million in revenues compared to $53.5 million in Q2 2019. The consensus Wall Street estimate was $39.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.